zkaxpf67

Property	Value
?:abstract	OBJECTIVES: Janus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to summarise the current understanding of JAKi use based on a systematic literature review (SLR) on efficacy and safety. METHODS: Existing data were evaluated by a steering committee and subsequently reviewed by a 29 person expert committee leading to the formulation of a consensus statement that may assist the clinicians, patients and other stakeholders once the decision is made to commence a JAKi. The committee included patients, rheumatologists, a gastroenterologist, a haematologist, a dermatologist, an infectious disease specialist and a health professional. The SLR informed the Task Force on controlled and open clinical trials, registry data, phase 4 trials and meta-analyses. In addition, approval of new compounds by, and warnings from regulators that were issued after the end of the SLR search date were taken into consideration. RESULTS: The Task Force agreed on and developed four general principles and a total of 26 points for consideration which were grouped into six areas addressing indications, treatment dose and comedication, contraindications, pretreatment screening and risks, laboratory and clinical follow-up examinations, and adverse events. Levels of evidence and strengths of recommendations were determined based on the SLR and levels of agreement were voted on for every point, reaching a range between 8.8 and 9.9 on a 10-point scale. CONCLUSION: The consensus provides an assessment of evidence for efficacy and safety of an important therapeutic class with guidance on issues of practical management.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/zkaxpf67_hasAnnotation_C0877248> <https://research.tib.eu/covid-19/entity/zkaxpf67_hasAnnotation_C3854325>
?:creator	<https://research.tib.eu/covid-19/entity/Nash%2C_Peter%3B_Kerschbaumer%2C_Andreas%3B_D%C3%B6rner%2C_Thomas%3B_Dougados%2C_Maxime%3B_Fleischmann%2C_Roy_M%3B_Geissler%2C_Klaus%3B_McInnes%2C_Iain%3B_Pope%2C_Janet_E%3B_van_der_Heijde%2C_D%C3%A9sir%C3%A9e%3B_Stoffer-Marx%2C_Michaela%3B_Takeuchi%2C_Tsutomu%3B_Trauner%2C_Michael%3B_Winthrop%2C_Kevin_L%3B_de_Wit%2C_Maarten%3B_Aletaha%2C_Daniel%3B_Baraliakos%2C_Xenofon%3B_Boehncke%2C_Wolf-Henning%3B_Emery%2C_Paul%3B_Isaacs%2C_John_D%3B_Kremer%2C_Joel%3B_Lee%2C_Eun_Bong%3B_Maksymowych%2C_Walter_P%3B_Voshaar%2C_Marieke%3B_Tam%2C_Lai-Shan%3B_Tanaka%2C_Yoshiya%3B_van_den_Bosch%2C_Filip%3B_Westhovens%2C_Ren%C3%A9%3B_Xavier%2C_Ricardo%3B_Smolen%2C_Josef_S>
?:doi	10.1136/annrheumdis-2020-218398
?:doi	<https://research.tib.eu/covid-19/entity/10.1136/annrheumdis-2020-218398>
?:journal	Ann_Rheum_Dis
?:license	cc-by-nc
?:pdf_json_files	document_parses/pdf_json/a57a4b3bd6296be3d4c3ae743df55924915a3f9b.json
?:pmc_json_files	document_parses/pmc_json/PMC7788060.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7788060>
?:pmid	<https://research.tib.eu/covid-19/entity/33158881.0>
?:pmid	33158881.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/zkaxpf67_HAS_C3854325_TREATS_C1290884>
?:sha_id	<https://research.tib.eu/covid-19/entity/a57a4b3bd6296be3d4c3ae743df55924915a3f9b>
?:source	Medline; PMC
?:title	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-11-06

Property

Value

?:abstract

OBJECTIVES: Janus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to summarise the current understanding of JAKi use based on a systematic literature review (SLR) on efficacy and safety. METHODS: Existing data were evaluated by a steering committee and subsequently reviewed by a 29 person expert committee leading to the formulation of a consensus statement that may assist the clinicians, patients and other stakeholders once the decision is made to commence a JAKi. The committee included patients, rheumatologists, a gastroenterologist, a haematologist, a dermatologist, an infectious disease specialist and a health professional. The SLR informed the Task Force on controlled and open clinical trials, registry data, phase 4 trials and meta-analyses. In addition, approval of new compounds by, and warnings from regulators that were issued after the end of the SLR search date were taken into consideration. RESULTS: The Task Force agreed on and developed four general principles and a total of 26 points for consideration which were grouped into six areas addressing indications, treatment dose and comedication, contraindications, pretreatment screening and risks, laboratory and clinical follow-up examinations, and adverse events. Levels of evidence and strengths of recommendations were determined based on the SLR and levels of agreement were voted on for every point, reaching a range between 8.8 and 9.9 on a 10-point scale. CONCLUSION: The consensus provides an assessment of evidence for efficacy and safety of an important therapeutic class with guidance on issues of practical management.

is ?:annotates of